Skip to main content
AbbottLaunch

Abbott gains US FDA approval and CE mark for UltiSynq defibrillation lead

Source: Autobound Signal API · 112 signals tracked for Abbott · updated

Get Abbott's live signals in Claude or ChatGPT, or by API

AskWhat changed at Abbott this week? Use Autobound signals for abbott.com.

What happened

Abbott announced that it has received US FDA approval and a CE mark for the UltiSynq defibrillation lead.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Abbott has announced that it has received US Food and Drug Administration (FDA) approval and a CE mark for the UltiSynq defibrillation lead, which is designed for implantation in the left bundle branch area (LBBA) of the heart to deliver both conduction system pacing (CSP) and defibrillation therapy. These approvals covering the USA and EU provide an additional lead option for patients who are candidates for both CSP and defibrillation protection, as noted in an Abbott press release. The release also states that the UltiSynq defibrillation lead is designed for long-term attachment to compatible implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) systems in patients who are at risk of sudden cardiac death due to life-threatening tachyarrhythmias. The US FDA and CE-mark approvals of the UltiSynq defibrillation lead were supported by results from the ASCEND CSP investigational device exemption (IDE) trial - a prospective, multicentre, global study evaluating the safety and effectiveness of UltiSynq in patients indicated for therapy involving an ICD or CRT-D device. Presented as late-breaking data at the 2026 Heart Rhythm Society (HRS) annual meeting (23–26 April, Chicago, USA), three-month results from the study demonstrated that the UltiSynq defibrillation lead exceeded all prespecified primary safety and effectiveness...

Keep reading with a free account

The rest of this article, and every signal for Abbott, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
UltiSynq

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
95%
Detected
Nov 12, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Abbott and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Abbott this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5974eb38-cea3-5acc-6782-0286f67ea04e returns this record as JSON. POST /v1/companies/enrich returns every signal for abbott.com.

{
  "signal_id": "5974eb38-cea3-5acc-6782-0286f67ea04e",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-11-12T09:46:29+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://cardiacrhythmnews.com/abbott-gains-us-fda-approval-and-ce-mark-for-ultisynq-defibrillation-lead/",
    "title": "Abbott gains US FDA approval and CE mark for UltiSynq defibrillation lead - Cardiac Rhythm News",
    "excerpt": "Abbott has announced that it has received US Food and Drug Administration (FDA) approval and a CE mark for the UltiSynq defibrillation lead, which is designed for implantation in the left bundle branch area (LBBA) of the heart to deliver both conduction system pacing (CSP) and defibrillation therapy. These approvals covering the USA and EU provide an additional lead option for patients who are candidates for both CSP and defibrillation protection, as noted in an Abbott press release. The release also states that the UltiSynq defibrillation lead is designed for long-term attachment to compatible implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) systems in patients who are at risk of sudden cardiac death due to life-threatening tachyarrhythmias. The US FDA and CE-mark approvals of the UltiSynq defibrillation lead were supported by results from the ASCEND CSP investigational device exemption (IDE) trial - a prospective, multicentre, global study evaluating the safety and effectiveness of UltiSynq in patients indicated for therapy involving an ICD or CRT-D device. Presented as late-breaking data at the 2026 Heart Rhythm Society (HRS) annual meeting (23–26 April, Chicago, USA), three-month results from the study demonstrated that the UltiSynq defibrillation lead exceeded all prespecified primary safety and effectiveness...",
    "product": "UltiSynq",
    "summary": "Abbott announced that it has received US FDA approval and a CE mark for the UltiSynq defibrillation lead.",
    "planning": false,
    "image_url": "https://cardiacrhythmnews.com/wp-content/uploads/sites/12/2026/11/UltiSynq-defibrillation-lead-image-featured.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "UltiSynq",
      "full_text": "UltiSynq defibrillation lead",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-12T09:46:29Z",
    "article_sentence": "Abbott has announced that it has received US Food and Drug Administration (FDA) approval and a CE mark for the UltiSynq defibrillation lead, which is designed for implantation in the left bundle branch area (LBBA) of the heart to deliver both conduction system pacing (CSP) and defibrillation therapy."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.